Mel'nichuk P V, Minich L N
Zh Nevropatol Psikhiatr Im S S Korsakova. 1979;79(8):1002-6.
Clinico-biochemical examinations of 55 patients suffering from various clinical forms of deforming myodystonia were performed. L-DOPA was used in 47 cases. A correlation between the therapeutic effect and the level of phenylacetylglutamine excretion was revealed. The increase of the phenylacetylglutamine excretion was an evidence of a positive result of the treatment that was noted in 36 patients (77%). A resistance to the drug was observed in cases when the phenylacetylglutamine excretion did not exceed its normal level. The quantitative determination of phenylacetylglutamine in the daily portion of the urine can be used as a prognostic test of the therapeutic efficacy of L-DOPA in patients with deforming myodystonia.
对55例患有各种临床类型变形性肌营养不良症的患者进行了临床生化检查。47例患者使用了左旋多巴。发现治疗效果与苯乙酰谷氨酰胺排泄水平之间存在相关性。苯乙酰谷氨酰胺排泄增加是治疗取得阳性结果的证据，36例患者（77%）出现了这种情况。当苯乙酰谷氨酰胺排泄未超过正常水平时，观察到对该药物有耐药性。对每日尿液样本中苯乙酰谷氨酰胺进行定量测定，可作为左旋多巴对变形性肌营养不良症患者治疗效果的预后测试。
